Exploiting Metabolic Vulnerabilities in Acute Myeloid Leukemia: Rationale and Evidence for Combining Metabolic Modulators with Conventional Chemotherapy
Usman Ali Shams, Fawad Inayat, Muhammad Asif Zeb, Maryam, Sulaiman Shams, Muhammad Jawad Ullah, Silvia Jiménez-Morales · 2026
Read Exploiting Metabolic Vulnerabilities in Acute Myeloid Leukemia: Rationale and Evidence for Combining Metabolic Modulators with Conventional Chemotherapy by Usman Ali Shams, Fawad Inayat, Muhammad Asif Zeb, Maryam, Sulaiman Shams, Muhammad Jawad Ullah, Silvia Jiménez-Morales (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13610817.txt.
Description
Usman Ali Shams and co-authors review a drug strategy against acute myeloid leukemia in this 2026 survey. This blood cancer grows from runaway marrow progenitors, and its cells rewire how they make energy. Those new habits create needs that healthy blood stem cells lack.
Drug families that block sugar burning, cell power plants, amino acid use, fat burning, and redox balance each get a chapter. For each, the review links how the drug pairs with standard chemotherapy and what lab and trial proof exists. Combo plans and safety hurdles close the survey. The authors see metabolism as a promising weak point, if trials pick patients by markers.
Catalog record
| CREATOR | Usman Ali Shams, Fawad Inayat, Muhammad Asif Zeb, Maryam, Sulaiman Shams, Muhammad Jawad Ullah, Silvia Jiménez-Morales |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |